Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 24,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2022, Forbes has recognized Grifols as one of the “Best Employers for Women,” one of “America’s Best Large Employers” and one of the “75 Best Companies to Work for” in Spain. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind. You will find a full version of our guidelines at https://www.grifols.com/en/grifols-social-media-community-guidelines

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. See our Community Guidelines: bit.ly/smcgl See our Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. In addition to the Corporate Headquarters, Amphastar has five manufacturing facilities located in the United States, China and Europe along with a state-of-the-art New Drug Research Center. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. We currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. Amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the U.S. enables it to establish significant market share upon the introduction of its new products.

For more than half a century, IVC has been producing some of the highest quality dietary supplements for leading retailers in the U.S. - as well as nutritional, prescription and OTC products for contract customers throughout the world. IVC’s ability to deliver on innovation, quality and supply chain efficiency has enabled us to become one of the fastest growing companies in the nutritional market.

Founded in 1895 by the Sisters of Divine Providence, OLLU offers bachelor's, master's and doctoral degrees through weekday, weekend, evening, and online settings in San Antonio, Houston and the Rio Grande Valley (La Feria). Overall enrollment is more than 3,300 undergraduate and graduate students. Academic units include the School of Business and Leadership, the College of Arts and Sciences, the College of Professional Studies, the Worden School of Social Service and the Woolfolk School of Communication Sciences and Disorders. OLLU has more than 24,000 alumni.

An American Vanguard Company (NYSE: AVD). AMVAC® is a solutions provider for global agriculture that is committed to technology, innovation, and sustainability. We focus on four innovation platforms: Proven Chemistries, Precision Agriculture, GreenSolutions™, and Sustainability Solutions for plant and soil health. www.AMVAC.com

Performing specific technical color education ● Lead more than 30 hands­ on seminars of of 3­6 hours for up to 20 participants, coordinating site and logistical accommodations with both Regis and Wella management by email and phone, to ensure rewarding and enriching events.

John Paul Mitchell Systems® (JPMS) is a top manufacturer of high-quality hair care products and styling tools through several brands including Paul Mitchell®, Awapuhi Wild Ginger®, Tea Tree, Pro Tools™, Neuro®, MITCH® and MVRCK®, plus professional hair color from brands including The Demi and Color XG®. JPMS was founded in 1980 by co-founders Paul Mitchell and John Paul DeJoria with more than 300 employees globally and Michaeline DeJoria as CEO. We were the first professional hair care company to take a stand against animal testing, and we continue our strong commitment to giving back by supporting a wide range of philanthropic causes both domestically and internationally. JPMS products can be purchased at professional salons, Paul Mitchell® Schools and through authorized online retailers. Join our team!

Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif.

Eckert & Ziegler Isotope Products, Inc. is a Hospital and Health Care company located in 24937 Ave Tibbitts, Santa Clarita, CA, United States.

The Swiss-based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides. With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.